Featured Articles

  1. FDA's Psychedelic Reckoning 11/27/2024

    Cybin CEO Doug Drysdale discusses learnings from psychedelic drug clinical trial missteps, provides examples of the benefits of FDA breakthrough therapy designation, and talks about why RFK Jr. as HHS Secretary could be a win for psychedelic drug developers.

  2. How To Lead a Company That's Disrupting An Industry 11/22/2024

    Pacira BioSciences CEO Frank D. Lee shares three core tenants to improve biopharmaceutical company leadership, especially companies with products capable of disrupting an established therapeutic area.

  3. Translating Hidden Gems Into Medicines 11/19/2024

    Reflecting on 20 years of experience working as a scientist in Big Pharma and biotech, Louise Modis, Ph.D., CSO at Amphista Therapeutics, shares the key elements necessary for successful drug discovery and development.

  4. CEO Panel Talks IRA Impact At Galien Forum 11/14/2024

    A panel of biopharmaceutical leaders convened at the Galien Forum discussed the impacts of the Inflation Reduction Act so far, and what's likely to come in the year ahead.

  5. Is Cash Pay The Right Model For Your Medicine? 11/13/2024

    A cash pay model for prescription drugs can help biopharmaceutical companies meet consumer expectations. However, the model isn't right for every product; out-of-pocket costs, and a capable pharmacy partner, are two key considerations.

  6. From Bike Mechanic To Surgeon To CEO 11/11/2024

    InflaRx cofounder and CEO Niels Riedemann, M.D. shares the overarching pillars that have shaped his career as a physician, surgeon, and biopharmaceutical leader.

  7. Mimicking The Hollywood Mindset To Develop Drugs In An Era Driven By Capital Markets 11/7/2024

    Traditional organizational structures often struggle to adapt to the dynamic nature of drug development; consultant Sid Parulkar offers another approach that borrows from the Hollywood film industry.

  8. Partnering To Advance Next Generation Treatments For Breast Cancer 11/5/2024

    Disease progression in metastatic breast cancer is a challenge that no single entity can solve alone. Breakthroughs in treatment and patient outcomes require collaborations that leverage expertise, insights, and capabilities across organizations.

  9. Science Does Not Sell Itself: Designing A Winning Pivotal Trial 11/1/2024

    Pivotal trial design can make or break a new therapy's commercial viability. This article explores how choosing the right patient population, endpoints, and comparator are critical for achieving a favorable outcome and maximizing a therapy's market potential.

  10. A Bioethicist Weighs In On Obesity Drugs 10/31/2024

    Anne Zimmerman, editor-in-chief of the Columbia University online journal, Voices in Bioethics discusses her concerns over the use of GLP-1 weight loss drugs in the U.S.